Cargando…

Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease

BACKGROUND: Changes in blood-brain barrier (BBB) functionality have been implicated in Parkinson's disease. This study aimed to investigate BBB transport of L-DOPA transport in conjunction with its intra-brain conversion, in both control and diseased cerebral hemispheres in the unilateral rat r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ravenstijn, Paulien GM, Drenth, Henk-Jan, O'Neill, Michael J, Danhof, Meindert, de Lange, Elizabeth CM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298802/ https://www.ncbi.nlm.nih.gov/pubmed/22316420 http://dx.doi.org/10.1186/2045-8118-9-4

Ejemplares similares

Readiness Potential in Parkinson's Disease: Effects of L-Dopa Therapy and Brain Transplants
por: Martínez, D. N. Velázquez, et al.
Publicado: (1992)

Differences in Brain Activity Between Dopa-Responsive and -Unresponsive Pain in Parkinson’s Disease
por: Zheng, Jin Hua, et al.
Publicado: (2022)

Deep brain stimulation for Parkinson's disease prior to L-dopa treatment: A case report
por: Servello, Domenico, et al.
Publicado: (2016)

Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease
por: Muthuraman, Muthuraman, et al.
Publicado: (2018)

Pre-dopa Deep Brain Stimulation: Is Early Deep Brain Stimulation Able to Modify the Natural Course of Parkinson’s Disease?
por: Porta, Mauro, et al.
Publicado: (2020)

The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid
por: Westerhout, Joost, et al.
Publicado: (2013)

Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota
por: Wang, Yan, et al.
Publicado: (2021)

Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models
por: Danhof, Meindert
Publicado: (2015)

A New Minimal-Stress Freely-Moving Rat Model for Preclinical Studies on Intranasal Administration of CNS Drugs
por: Stevens, Jasper, et al.
Publicado: (2009)

Pharmacokinetic Modeling of Non-Linear Brain Distribution of Fluvoxamine in the Rat
por: Geldof, Marian, et al.
Publicado: (2007)

Dopa Responsive Slow Orthostatic Tremor in Parkinson’s Disease
por: Lee, Suk Yoon, et al.
Publicado: (2011)

Molecular Effects of L-dopa Therapy in Parkinson’s Disease
por: Dorszewska, Jolanta, et al.
Publicado: (2014)

Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease
por: Athulya, RT, et al.
Publicado: (2020)

L-Dopa Modulation of Brain Connectivity in Parkinson’s Disease Patients: A Pilot EEG-fMRI Study
por: Evangelisti, Stefania, et al.
Publicado: (2019)

Revisiting the L-Dopa Response as a Predictor of Motor Outcomes After Deep Brain Stimulation in Parkinson’s Disease
por: Lin, Zhengyu, et al.
Publicado: (2021)

Radiation-induced Brain Calcification Leads to L-dopa-resistant Parkinsonism and Cerebellar Ataxia
por: Shimada, Tomoyo, et al.
Publicado: (2022)

Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson’s Disease
por: dos Santos Pereira, Maurício, et al.
Publicado: (2021)

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
por: Stefano, George B., et al.
Publicado: (2012)

DOPA-sparing strategy in the treatment of young onset Parkinson's disease
por: Rana, Abdul Qayyum, et al.
Publicado: (2016)

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning
por: Chagraoui, Abdeslam, et al.
Publicado: (2019)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

l-Dopa and Brain Serotonin System Dysfunction
por: Stansley, Branden J., et al.
Publicado: (2015)

Is DOPA-Responsive Hypokinesia Responsible for Bimanual Coordination Deficits in Parkinson’s Disease?
por: Almeida, Quincy J., et al.
Publicado: (2013)

Novel GCH1 variant in Dopa-responsive dystonia and Parkinson's disease
por: Lewthwaite, A.J., et al.
Publicado: (2015)

Orbitofrontal (18)F-DOPA Uptake and Movement Preparation in Parkinson's Disease
por: Marinelli, Lucio, et al.
Publicado: (2015)

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
por: Hoon, Monique, et al.
Publicado: (2017)

Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
por: Bello, Fabio Del, et al.
Publicado: (2019)

Predictive timing functions of cortical beta oscillations are impaired in Parkinson's disease and influenced by L-DOPA and deep brain stimulation of the subthalamic nucleus
por: Gulberti, A., et al.
Publicado: (2015)

The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects
por: de Lange, Elizabeth CM
Publicado: (2013)

Anatomical Correlates of Uncontrollable Laughter With Unilateral Subthalamic Deep Brain Stimulation in Parkinson’s Disease
por: Huang, Yonglu, et al.
Publicado: (2018)

Comparison of subthalamic unilateral and bilateral theta burst deep brain stimulation in Parkinson’s disease
por: Gülke, Eileen, et al.
Publicado: (2023)

The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment
por: Managò, Francesca, et al.
Publicado: (2012)

Pilot study of atomoxetine in patients with Parkinson’s disease and dopa-unresponsive Freezing of Gait
por: Revuelta, Gonzalo J., et al.
Publicado: (2015)

L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson’s Disease
por: Blosser, Joshua A., et al.
Publicado: (2020)

Individual Magnetoencephalography Response Profiles to Short-Duration L-Dopa in Parkinson’s Disease
por: Peña, Edgar, et al.
Publicado: (2021)

In situ continuous Dopa supply by responsive artificial enzyme for the treatment of Parkinson’s disease
por: Fang, Xiao, et al.
Publicado: (2023)

A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations
por: Yamamoto, Yumi, et al.
Publicado: (2016)

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
por: Huh, Eugene, et al.
Publicado: (2019)

Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson’s disease
por: Wiesen, Tom, et al.
Publicado: (2022)

Design and conduct considerations for studies in patients with impaired renal function
por: Ravenstijn, Paulien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_40rbs0uieis85vbkk1hvremn2g